Breaking News

Quotient Clinical Begins 50th RapidFACT Program

By Kristin Brooks | February 6, 2014

Translational platform incorporates real-time GMP manufacturing and clinical testing

Quotient Clinical, a translational pharmaceutics company, began its 50th RapidFACT (Rapid Formulation development And Clinical Testing) program. RapidFACT was developed in 2008 with the goal of transforming the process of optimizing drug product formulations. According to the company, this service has now been proven to accelerate program timelines by at least 50% and reduce costs. Quotient’s translational pharmaceutics platform incorporates realtime GMP manufacturing and clinical testing, which enables formulation selection to be supported by emerging clinical data.
RapidFACT has been deployed in early development and life cycle management programs to develop oral, inhaled, dermal and ocular drug products. These programs have focused on optimizing drug products for once- or twice-daily dosing, or addressing poor solubility. 
Mark Egerton, chief executive officer of Quotient Clinical, said, "RapidFACT was launched in response to the challenges our customers told us they were confronting in their development programs.  We are pleased that the potential benefits we identified in 2008 have translated into real timeline reductions and cost savings in all of our RapidFACT programs. Ultimately, this approach is helping our customers to address many of the R&D productivity issues prevalent in the industry today."

Related Packaging:

Related Compliance:

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials